SMC says “no” to Amgen and Janssen multiple myeloma drugs.
Health systems should fund more treatments for chronic diseases, says EFPIA
A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
Patients could be denied treatments, says BIA
Afinitor finally recommended after rejection in 2011.
Leela Barham examines the approach of the Institute for Clinical and Economic Review.
What could be the impact of proposed new ‘budget impact threshold’ for drugs?